全文获取类型
收费全文 | 3745篇 |
免费 | 218篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 95篇 |
妇产科学 | 92篇 |
基础医学 | 396篇 |
口腔科学 | 52篇 |
临床医学 | 503篇 |
内科学 | 585篇 |
皮肤病学 | 86篇 |
神经病学 | 259篇 |
特种医学 | 93篇 |
外科学 | 508篇 |
综合类 | 48篇 |
一般理论 | 4篇 |
预防医学 | 559篇 |
眼科学 | 136篇 |
药学 | 291篇 |
中国医学 | 3篇 |
肿瘤学 | 241篇 |
出版年
2023年 | 30篇 |
2022年 | 50篇 |
2021年 | 100篇 |
2020年 | 50篇 |
2019年 | 97篇 |
2018年 | 93篇 |
2017年 | 83篇 |
2016年 | 85篇 |
2015年 | 95篇 |
2014年 | 136篇 |
2013年 | 174篇 |
2012年 | 306篇 |
2011年 | 308篇 |
2010年 | 168篇 |
2009年 | 125篇 |
2008年 | 229篇 |
2007年 | 237篇 |
2006年 | 236篇 |
2005年 | 241篇 |
2004年 | 207篇 |
2003年 | 195篇 |
2002年 | 158篇 |
2001年 | 44篇 |
2000年 | 38篇 |
1999年 | 37篇 |
1998年 | 31篇 |
1997年 | 24篇 |
1996年 | 23篇 |
1995年 | 24篇 |
1994年 | 17篇 |
1993年 | 11篇 |
1992年 | 25篇 |
1991年 | 33篇 |
1990年 | 27篇 |
1989年 | 20篇 |
1988年 | 14篇 |
1987年 | 17篇 |
1986年 | 18篇 |
1985年 | 13篇 |
1984年 | 16篇 |
1983年 | 12篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1976年 | 7篇 |
1975年 | 7篇 |
1974年 | 7篇 |
1973年 | 10篇 |
1972年 | 7篇 |
1971年 | 12篇 |
1970年 | 8篇 |
排序方式: 共有3968条查询结果,搜索用时 562 毫秒
71.
Jessica Ayers Jamie Cook Rachel A. Koenig Evan M. Sisson Dave L. Dixon 《Current atherosclerosis reports》2018,20(6):29
Purpose of Review
This review examines recent randomized clinical trials evaluating the role of coenzyme Q10 (CoQ10) in the management of coronary heart disease.Recent Findings
CoQ10 is one of the most commonly used dietary supplements in the USA. Due to its antioxidant and anti-inflammatory effects, CoQ10 has been studied extensively for possible use in managing coronary heart disease. One of the most common applications of CoQ10 is to mitigate statin-associated muscle symptoms (SAMS) based on the theory that SAMS are caused by statin depletion of CoQ10 in the muscle. Although previous studies of CoQ10 for SAMS have produced mixed results, CoQ10 appears to be safe. Because CoQ10 is a cofactor in the generation of adenosine triphosphate, supplementation has also recently been studied in patients with heart failure, which is inherently an energy deprived state. The Q-SYMBIO trial found that CoQ10 supplementation in patients with heart failure not only improved functional capacity, but also significantly reduced cardiovascular events and mortality. Despite these positive findings, a larger prospective trial is warranted to support routine use of CoQ10. Less impressive are the effects of CoQ10 on specific cardiovascular risk factors such as blood pressure, dyslipidemia, and glycemic control.Summary
Current evidence does not support routine use of CoQ10 in patients with coronary heart disease. Additional studies are warranted to fully determine the benefit of CoQ10 in patients with heart failure before including it in guideline-directed medical therapy.72.
Apoor S Gami Dave O Hodge Regina M Herges Eric J Olson Jiri Nykodym Tomas Kara Virend K Somers 《Journal of the American College of Cardiology》2007,49(5):565-571
OBJECTIVES: This study sought to identify whether obesity and obstructive sleep apnea (OSA) independently predict incident atrial fibrillation/flutter (AF). BACKGROUND: Obesity is a risk factor for AF, and OSA is highly prevalent in obesity. Obstructive sleep apnea is associated with AF, but it is unknown whether OSA predicts new-onset AF independently of obesity. METHODS: We conducted a retrospective cohort study of 3,542 Olmsted County adults without past or current AF who were referred for an initial diagnostic polysomnogram from 1987 to 2003. New-onset AF was assessed and confirmed by electrocardiography during a mean follow-up of 4.7 years. RESULTS: Incident AF occurred in 133 subjects (cumulative probability 14%, 95% confidence interval [CI] 9% to 19%). Univariate predictors of AF were age, male gender, hypertension, coronary artery disease, heart failure, smoking, body mass index, OSA (hazard ratio 2.18, 95% CI 1.34 to 3.54) and multiple measures of OSA severity. In subjects <65 years old, independent predictors of incident AF were age, male gender, coronary artery disease, body mass index (per 1 kg/m2, hazard ratio 1.07, 95% CI 1.05 to 1.10), and the decrease in nocturnal oxygen saturation (per 0.5 U log change, hazard ratio 3.29, 95% CI 1.35 to 8.04). Heart failure, but neither obesity nor OSA, predicted incident AF in subjects > or =65 years of age. CONCLUSIONS: Obesity and the magnitude of nocturnal oxygen desaturation, which is an important pathophysiological consequence of OSA, are independent risk factors for incident AF in individuals <65 years of age. 相似文献
73.
Steven Novick Yan Shen Harry Yang John Peterson Dave LeBlond Stan Altan 《Journal of biopharmaceutical statistics》2015,25(2):351-371
Dissolution (or in vitro release) studies constitute an important aspect of pharmaceutical drug development. One important use of such studies is for justifying a biowaiver for post-approval changes which requires establishing equivalence between the new and old product. We propose a statistically rigorous modeling approach for this purpose based on the estimation of what we refer to as the F2 parameter, an extension of the commonly used f2 statistic. A Bayesian test procedure is proposed in relation to a set of composite hypotheses that capture the similarity requirement on the absolute mean differences between test and reference dissolution profiles. Several examples are provided to illustrate the application. Results of our simulation study comparing the performance of f2 and the proposed method show that our Bayesian approach is comparable to or in many cases superior to the f2 statistic as a decision rule. Further useful extensions of the method, such as the use of continuous-time dissolution modeling, are considered. 相似文献
74.
75.
Akshay Gopinathan Nair Swathi Kaliki Dilip Kumar Mishra Tarjani Vivek Dave Milind N Naik 《Indian journal of ophthalmology》2015,63(7):620-622
Schwannomas are benign, encapsulated, primary neurilemmal tumors composed of proliferating Schwann cells. Schwannomas are commonly seen in the orbit, but are rare on the epibulbar surface. Herein, we report a case of a 12-year-old boy who presented to us with a slow-growing painless subconjunctival mass in the left eye. There was no intraocular extension of the mass and intra-operatively, the mass could be clearly delineated and was excised off the underlying sclera. Histopathological examination of the mass showed typical features of schwannoma and immunohistochemistry helped to confirm the diagnosis. There was no recurrence of the lesion observed at follow-up 26 months after surgery. Here, we describe this uncommon tumor and review the available literature. Although rare, an epibulbar schwannoma should be considered in the differential diagnosis of an amelanotic, painless subconjunctival nodular mass. Excision of the lesion is the recommended treatment. 相似文献
76.
E H Shao V Sivagnanavel A Dabbagh R Dave S Tempest-Roe F W K Tam S R Taylor 《Eye (London, England)》2015,29(4):569-573
Purpose
To investigate whether intravitreal ranibizumab injections administered to a child alter systemic plasma levels of total and free VEGF 165.Methods
A 9-year-old child sustained a choroidal rupture from blunt trauma. He subsequently developed a secondary choroidal neovascular membrane, which was treated with five ranibizumab injections over a period of 8 months. Peripheral venous blood samples were taken at each visit over a period of 12 months and plasma was extracted. Plasma VEGF 165 levels were determined using enzyme-linked immunosorbent assay and were assayed both pre- and post-immunodepletion to remove complexed VEGF.Results
Plasma VEGF 165 levels proved labile following intravitreal injection of ranibizumab. Levels increased by 30% above baseline following the first intravitreal ranibizumab injection, but then returned to baseline despite two subsequent injections. There was then a rebound increase of 67% in total plasma VEGF levels following a further injection, which remained above baseline for 12 weeks despite two further intravitreal ranibizumab injections. Baseline levels were re-attained 26 weeks after the final injection.Conclusions
These results suggest intravitreal ranibizumab injections can cause significant, multiphasic changes in systemic VEGF levels. This may be of particular clinical significance in children as VEGF is known to be vital in the development of major organs, in addition to its role in the maintenance of normal organ function in adults. 相似文献77.
Kathryn Fitch Thomas Weisman Tyler Engel Adam Turpcu Helen Blumen Yamina Rajput Purav Dave 《American Health & Drug Benefits》2015,8(6):300-308
Background
Diabetic retinopathy is one of the most common complications of diabetes. The screening of patients with diabetes to detect retinopathy is recommended by several professional guidelines but is an underutilized service.Objective
To analyze the relationship between the frequency of retinopathy screening and the cost of care in adult patients with diabetes.Methods
Truven Health MarketScan commercial databases (2000–2013) were used to identify the diabetic population aged 18 to 64 years for the performance of a 2001–2013 annual trend analysis of patients with type 1 and type 2 diabetes and a 10-year longitudinal analysis of patients with newly diagnosed type 2 diabetes. In the trend analysis, the prevalence of diabetes, screening rate, and allowed cost per member per month (PMPM) were calculated. In the longitudinal analysis, data from 4 index years (2001–2004) of patients newly diagnosed with type 2 diabetes were combined, and the costs were adjusted to be comparable to the 2004 index year cohort, using the annual diabetes population cost trends calculated in the trend analysis. The longitudinal population was segmented into the number of years of diabetic retinopathy screening (ie, 0, 1–4, 5–7, and 8–10), and the relationship between the years of screening and the PMPM allowed costs was analyzed. The difference in mean incremental cost between years 1 and 10 in each of the 4 cohorts was compared after adjusting for explanatory variables.Results
In the trend analysis, between 2001 and 2013, the prevalence of diabetes increased from 3.93% to 5.08%, retinal screening increased from 26.27% to 29.58%, and the average total unadjusted allowed cost of care for each patient with diabetes increased from $822 to $1395 PMPM. In the longitudinal analysis, the difference between the screening cohorts’ mean incremental cost increase was $185 between the 0- and 1–4–year cohorts (P <.003) and $202 between the 0- and 5–7–year cohorts (P <.023). The cost differences between the other cohorts, including $217 between the 0- and 8–10–year cohorts (P <.066), were not statistically significant.Conclusions
Based on our analysis, the annual retinopathy screening rate for patients with diabetes has remained low since 2001, and has been well below the guideline-recommended screening levels. For patients with type 2 diabetes, the mean increase in healthcare expenditures over a 10-year period after diagnosis is not statistically different among those with various retinopathy screening rates, although the increase in healthcare spending is lower for patients with diabetes who were not screened for retinopathy compared with patients who did get screened. 相似文献78.
Dave Singh 《British journal of clinical pharmacology》2015,79(5):695-708
Fixed dose combination (FDC) dual bronchodilators that co-administer a long acting β2-adrenoceptor agonist (LABA) and a long acting muscarinic antagonist (LAMA) are a new class of inhaled treatment for chronic obstructive pulmonary disease (COPD). This review focuses on the clinical evidence for the benefit of LABA/LAMA FDCs compared with monocomponent treatments, and also compared with active comparators that are widely used for the treatment of COPD, namely tiotropium and salmeterol-fluticasone. Novel FDC dual bronchodilators include QVA149 and umeclidinium/vilanterol (UMEC/VI). Long term clinical trials show that QVA149 and UMEC/VI are superior to monocomponent therapy in terms of trough forced expiratory volume in 1 s (FEV1), although the FEV1 improvement was limited to approximately 80–90% of the added monocomponent values. This suggests that the effect of combining a LABA and a LAMA is not fully additive. LABA/LAMA FDC were associated with the largest mean changes in symptoms and health status that were above the minimal clinically important difference, in contrast to the monocomponents. Furthermore, these LABA/LAMA FDCs demonstrated superiority over the active comparators tiotropium and salmeterol-fluticasone in terms of trough FEV1 and patient-reported outcomes. LABA/LAMA FDCs offer a simplified means of maximizing bronchodilation for COPD patients, with the improvements in lung function being mirrored by benefits in terms of symptoms and exacerbations. The use of LABA/LAMA FDCs in clinical practice is set to grow and further studies are needed to define their optimal place in treatment guidelines. 相似文献
79.
Jennifer M. Logue Elisa Zucchetti Christina A. Bachmeier Gabriel S. Krivenko Victoria Larson Daniel Ninh Giovanni Grillo Biwei Cao Jongphil Kim Julio C. Chavez Aliyah Baluch Farhad Khimani Aleksandr Lazaryan Taiga Nishihori Hien D. Liu Javier Pinilla-Ibarz Bijal D. Shah Rawan Faramand Anna E. Coghill Marco L. Davila Bhagirathbhai R. Dholaria Michael D. Jain Frederick L. Locke 《Haematologica》2021,106(4):978
CD19 chimeric antigen receptor T (CAR T)-cell therapy with axicabtagene ciloleucel (axi-cel) for relapsed or refractory (R/R) large B-cell lymphoma (LBCL) may lead to durable remissions, however, prolonged cytopenias and infections may occur. In this single center retrospective study of 85 patients, we characterized immune reconstitution and infections for patients remaining in remission after axi-cel for LBCL. Prolonged cytopenias (those occurring at or after day 30 following infusion) were common with ≥grade 3 neutropenia seen in 21 of 70 (30%) patients at day 30 and persisting in 3 of 31 (9.7%) patients at 1 year. B cells were undetectable in 30 of 34 (88.2%) patients at day 30, but were detected in 11 of 19 (57.9%) at 1 year. Median immunoglobulin G levels levels reached a nadir at day 180. By contrast, CD4 T cells decreased from baseline and were persistently low with a median CD4 count of 155 cells/mL at 1 year after axi-cel (n=19, range: 33– 269). In total, 23 of 85 (27.1%) patients received intravenous immunoglobulins after axi-cel, and 34 of 85 (40%) received granulocyte-colony stimulating factor. Infections in the first 30 days occurred in 31 of 85 (36.5%) patients, of which 11 of 85 (12.9%) required intravenous antibiotics or hospitalization (“severe”) and were associated with cytokine release syndrome, neurotoxicity, tocilizumab use, corticosteroid use, and bridging therapy on univariate analyses. After day 30, seven severe infections occurred, with no late deaths due to infection. Prolonged cytopenias are common following axi-cel therapy for LBCL and typically recover with time. Most patients experience profound and prolonged CD4 T-cell immunosuppression without severe infection. 相似文献
80.
Pradyuman Dave M.D. Jose Romeu M.D. Allan Selbst M.D. 《The American journal of gastroenterology》1983,78(11):745-746
The mortality rate in spontaneous bacterial peritonitis is reportedly high. Patients rarely survive the initial infection. Most patients die either because of infection or end-stage liver disease. A patient with alcoholic cirrhosis and portal hypertension with five distinct episodes of spontaneous bacterial peritonitis over a 2 1/2-year period is described. 相似文献